Tadalafil Tablet, Film Coated
Product Images NDC 76420-642

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 76420-642). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Asclemed Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Label)

Labels for Tadalafil Tablets USP 5 mg, film-coated oral tablets, showing three package sizes: 30, 60, and 90 tablets. Labeled by Enovachem Pharmaceuticals, with NDC numbers 76420-642-30, 76420-642-60, and 76420-642-90 respectively. Manufactured for Macleods Pharma USA, Inc., featuring yellow/almond-shaped tablets and a barcode on each label. Storage and caution information is included.*

FDA Label Image

Fig1 (Tadalafil Figure 1)

A set of four line graphs showing the difference in blood pressure measurements between tadalafil and placebo over time (hours). The graphs display standing systolic blood pressure, standing diastolic blood pressure, supine systolic blood pressure, and supine diastolic blood pressure with time in hours on the x-axis and difference in mmHg on the y-axis.*

FDA Label Image

Fig (Tadalafil Figure 2)

A two-panel line graph showing the effect of Tadalafil 20 mg with doxazosin 8 mg versus placebo with doxazosin 8 mg on systolic blood pressure (BP) changes over 24 hours. The top panel shows standing systolic BP changes (mmHg), and the bottom panel shows supine systolic BP changes (mmHg), both plotted against time post-dose (hours).*

FDA Label Image

Fig (Tadalafil Figure 3)

A line graph showing changes in systolic blood pressure (mmHg) over 12 hours after administration of tadalafil or placebo combined with doxazosin. The graph compares four conditions: 20 mg tadalafil at 08:00 with 8 mg doxazosin, placebo at 08:00 with 8 mg doxazosin, 20 mg tadalafil at 20:00 with 8 mg doxazosin, and placebo at 20:00 with 8 mg doxazosin.*

FDA Label Image

Fig (Tadalafil Figure 4)

A line graph depicting plasma tadalafil concentration (μg/L) over time (hours) following different dosing regimens. The graph compares a single 20-mg tadalafil dose, a single 5-mg tadalafil dose, and once-daily 5-mg tadalafil after 5 consecutive days, illustrating the concentration decline and variability over approximately 120 hours.*

FDA Label Image

Fig (Tadalafil Figure 5)

A line graph comparing the change from baseline in IPSS total score over 12 weeks between Tadalafil 5 mg tablets and placebo. The x-axis represents the duration of treatment in weeks, and the y-axis shows the change in score. The graph indicates greater improvement with Tadalafil compared to placebo.*

FDA Label Image

Fig (Tadalafil Figure 6)

A line graph showing the change from baseline in IPSS total score over 12 weeks for Tadalafil tablets 5 mg versus placebo. The x-axis represents duration of treatment in weeks, and the y-axis shows change in score. Tadalafil shows a greater decrease in score compared to placebo over time, with a significant difference at 4 weeks (p<0.01).*

FDA Label Image

Fig (Tadalafil Figure 7)

A line graph titled 'Weeks of Therapy' showing least-squares mean change from baseline over a 26-week period. It compares Tadalafil/Finasteride versus Placebo/Finasteride treatments, with distinct markers for each group and annotations for statistical significance (p-values). The vertical axis measures change from baseline, and the horizontal axis shows time points at 0, 4, 12, and 26 weeks.*

FDA Label Image

Fig (Tadalafil Figure 8)

A line graph illustrating the change from baseline in IPSS Total Score over 12 weeks of treatment, comparing Tadalafil 5 mg tablets to placebo. The x-axis represents treatment duration in weeks, and the y-axis shows the change in score. Data points indicate a significant improvement with Tadalafil versus placebo (p<0.01).*

FDA Label Image

Stru (Tadalafil Structure)

Chemical structure of Tadalafil, the active ingredient shown in the image, depicting its molecular framework including rings and functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.